Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 3

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Hepatocellular 40Carcinoma, Non-Small-Cell Lung 31Triple Negative Breast Neoplasms 23Nasopharyngeal Carcinoma 23Stomach Neoplasms 22Esophageal Neoplasms 20Esophageal Squamous Cell Carcinoma 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 14Colorectal Neoplasms 12Uterine Cervical Neoplasms 11Sarcoma 10Pancreatic Neoplasms 9Lung Neoplasms 9Recurrence 7Neoplasm Metastasis 7Melanoma 6Liver Neoplasms 6Hodgkin Disease 6Cholangiocarcinoma 6Biliary Tract Neoplasms 5Advanced Gastric Cancer 5Small Cell Lung Carcinoma 4Osteosarcoma 4Neoplasms 4Locally Advanced Gastric Cancer 4Advanced Solid Tumor 4Solid Tumor 3Respiratory Tract Diseases 3Rectal Neoplasms 3

Interventions

Pemetrexed 14Carboplatin 13osimertinib 11Drug Therapy 9aflutinib 8Gefitinib 8Radiotherapy 6Docetaxel 6Cisplatin 6pembrolizumab 5anlotinib 5Radiosurgery 5Paclitaxel 5icotinib 4Vinorelbine 4Gemcitabine 4Erlotinib Hydrochloride 4tislelizumab 3camrelizumab 3apatinib 3HM781-36B 3toripalimab 2spartalizumab 2rezivertinib 2dacomitinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NSCLC × camrelizumab × Clear all
NCT05547737 2022-09-21

NSCLC

Henan Cancer Hospital

Unknown
500 enrolled
Thoracic

NSCLC

NCT05005468 2021-08-13

CAMFA-L

Shanghai Chest Hospital

Phase 2 Unknown
61 enrolled
Thoracic

NSCLC

NCT04506242 2020-09-09

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
74 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡